Immune Checkpoint Inhibitors Clinical Trials

10 recruiting

Immune Checkpoint Inhibitors Trials at a Glance

18 actively recruiting trials for immune checkpoint inhibitors are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Montpellier, Changsha, and Angers. Lead sponsors running immune checkpoint inhibitors studies include Second Xiangya Hospital of Central South University, Centre Hospitalier Universitaire, Amiens, and Beijing Chao Yang Hospital.

Browse immune checkpoint inhibitors trials by phase

Treatments under study

About Immune Checkpoint Inhibitors Clinical Trials

Looking for clinical trials for Immune Checkpoint Inhibitors? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immune Checkpoint Inhibitors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immune Checkpoint Inhibitors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting

Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

Lung CancerVenous ThromboembolismArterial Thromboembolism+1 more
Beijing Chao Yang Hospital2,400 enrolled5 locationsNCT06950697
Recruiting
Phase 3

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Urinary Bladder NeoplasmsImmune Checkpoint InhibitorsMethotrexate+4 more
AstraZeneca150 enrolled59 locationsNCT06960577
Recruiting
Phase 2

Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction

Stomach NeoplasmsImmune Checkpoint Inhibitors
Xijing Hospital116 enrolled5 locationsNCT06576921
Recruiting

A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

Immune Checkpoint InhibitorsArthritisPolymyalgia Rheumatica
M.D. Anderson Cancer Center20 enrolled1 locationNCT06647134
Recruiting

Observational Cohort Study of Chronic Viral Infection in the Central Nervous System

Immune Checkpoint InhibitorsProgressive Multifocal Leukoencephalopathy
Peking Union Medical College Hospital66 enrolled1 locationNCT07512518
Recruiting
Phase 2

JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial

Immune Checkpoint Inhibitors (ICI)-Related Dermatitis
Shixiu Wu35 enrolled1 locationNCT06715982
Recruiting

The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study

Unresectable Hepatocellular CarcinomaPsychological DistressHCC - Hepatocellular Carcinoma+2 more
Guilin Medical University, China700 enrolled5 locationsNCT07141056
Recruiting
Phase 1

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

MelanomaNeoplasmsNeoplasms by Site+7 more
Yana Najjar50 enrolled2 locationsNCT04572451
Recruiting

Cardiac Magnetic Resonance Monitoring of Immune Checkpoint Inhibitor-related Cardiotoxicity

Immune Checkpoint Inhibitors, Cardiotoxicity
West China Second University Hospital22 enrolled1 locationNCT06132984
Recruiting
Not Applicable

Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment

ImmunotherapyImmune Checkpoint InhibitorsImmune-related Adverse Event+1 more
Centre Hospitalier Universitaire, Amiens150 enrolled1 locationNCT05813418
Recruiting

The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer

Lung CancerSleep DisturbanceCancer, Treatment-Related+1 more
Second Xiangya Hospital of Central South University1,270 enrolled1 locationNCT06975384
Recruiting

Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis

Cancer PatientsLiver InjurySecondary to Immune Checkpoint Inhibitors
University Hospital, Montpellier250 enrolled1 locationNCT06864481
Recruiting

Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis

Immune Checkpoint Inhibitors-induced ColitisAdvanced Melanoma Skin Cancer, Non-small Cell Lung Carcinoma, Kidney AdenocarcinomaIleo-colitis+1 more
Fondazione IRCCS Policlinico San Matteo di Pavia250 enrolled1 locationNCT06899789
Recruiting

The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)

Lung CancerCancer, Treatment-RelatedPsychological Stress+1 more
Second Xiangya Hospital of Central South University750 enrolled1 locationNCT05477979
Recruiting
Phase 2

Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma

Hepatocellular CarcinomaImmune Checkpoint InhibitorsSecond-line Treatment+1 more
Sun Yat-sen University36 enrolled1 locationNCT06446154
Recruiting
Phase 2

Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)Neoantigen-loaded Dendritic Cell VaccineImmune Checkpoint Inhibitors (ICIs)
Sichuan University165 enrolled1 locationNCT06675201
Recruiting

A Clinical Study on the Analysis of Risk Factors for the Occurrence of PD-1/PD-L1 Inhibitor-associated Liver Injury in Lung Cancer Patients

Immune Checkpoint InhibitorsLiver Injury
Zhejiang University2,000 enrolled1 locationNCT06402981
Recruiting

Predictors of Immune Related Adverse Events from the use of the Immunotherapy in Patients with Cancer

Solid Malignancies where patients are receiving immune checkpoint inhibitors - either alone or in combination with other anti-cancer agents
Western Sydney University120 enrolled2 locationsACTRN12621001146886